Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Ishibashi, Yuji ^a   Matsui, Takanori ^a   Ueda, Seiji ^a   Fukami, Kei ^a   Yamagishi, Sho ichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AGEs; Diabetes; Endothelial cells; PAR 1; RAGE; Rivaroxaban

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BLOOD CLOTTING FACTOR 10A; FR 171113; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; RIVAROXABAN; THROMBIN; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ARTICLE; BLOOD CLOTTING; CELL DAMAGE; CELL LEVEL; CITRATED PLASMA; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; MOLECULAR INTERACTION; PLASMA; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION;

BENZAMIDES; CITRIC ACID; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMATION MEDIATORS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RECEPTOR, PAR-1; THIAZOLIDINES; UP-REGULATION;

EID: 84899572841     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-60     Document Type: Article

References (38)

1. Vlassara H, Bucala R. Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Diabetes 1996, 45(Suppl 3):S65-66.
2. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988, 318:1315-1321. 10.1056/NEJM198805193182007, 3283558.
3. Rahbar S. Novel inhibitors of glycation and AGE formation. Cell Biochem Biophys 2007, 48:147-157. 10.1007/s12013-007-0021-x, 17709884.
4. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001, 108:261-268. 10.1172/JCI11771, 203021, 11457879.
5. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, D'Agati VD, Schmidt AM. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003, 162:1123-1137. 10.1016/S0002-9440(10)63909-0, 1851245, 12651605.
6. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005, 11:2279-2299. 10.2174/1381612054367300, 16022668.
7. Yamagishi S, Nakamura K, Matsui T, Noda Y, Imaizumi T. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. Curr Pharm Des 2008, 14:487-495. 10.2174/138161208783597416, 18289075.
8. Jandeleit-Dahm K, Cooper ME. The role of AGEs in cardiovascular disease. Curr Pharm Des 2008, 14:979-986. 10.2174/138161208784139684, 18473849.
9. Tahara N, Yamagishi S, Takeuchi M, Honda A, Tahara A, Nitta Y, Kodama N, Mizoguchi M, Kaida H, Ishibashi M, Hayabuchi N, Matsui T, Imaizumi T. Positive association between serum level of glyceraldehyde-derived advanced glycation end products and vascular inflammation evaluated by [(18)F]fluorodeoxyglucose positron emission tomography. Diabetes Care 2012, 35:2618-2625. 10.2337/dc12-0087, 3507595, 22912424.
10. Takenaka K, Yamagishi S, Matsui T, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Curr Neurovasc Res 2006, 3:73-77. 10.2174/156720206775541804, 16472128.
11. Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes. Diab Vasc Dis Res 2010, 7:260-273. 10.1177/1479164110383723, 20847109.
12. Piazza G, Goldhaber SZ, Kroll A, Goldberg RJ, Emery C, Spencer FA. Venous thromboembolism in patients with diabetes mellitus. Am J Med 2012, 125:709-716. 10.1016/j.amjmed.2011.12.004, 3424058, 22560173.
13. Klem I, Wehinger C, Schneider B, Hartl E, Finsterer J, Stöllberger C. Diabetic atrial fibrillation patients: mortality and risk for stroke or embolism during a 10-year follow-up. Diabetes Metab Res Rev 2003, 19:320-328. 10.1002/dmrr.386, 12879410.
14. Yamagishi S, Fujimori H, Yonekura H, Yamamoto Y, Yamamoto H. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia 1998, 41:1435-1441. 10.1007/s001250051089, 9867210.
15. Bierhaus A, Illmer T, Kasper M, Luther T, Quehenberger P, Tritschler H, Wahl P, Ziegler R, Müller M, Nawroth PP. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 1997, 96:2262-2271. 10.1161/01.CIR.96.7.2262, 9337199.
16. Yamagishi S, Nakamura K, Matsui T, Inagaki Y, Takenaka K, Jinnouchi Y, Yoshida Y, Matsuura T, Narama I, Motomiya Y, Takeuchi M, Inoue H, Yoshimura A, Bucala R, Imaizumi T. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem 2006, 281:20213-20220. 10.1074/jbc.M602110200, 16707486.
17. Yamagishi S, Kikuchi S, Nakamura K, Matsui T, Makino T, Norisugi O, Shimizu T, Inoue H, Imaizumi T. Pigment epithelium-derived factor (PEDF) blocks angiotensin II-induced T cell adhesion to endothelial cells by suppressing intercellular adhesion molecule-1. Horm Metab Res 2006, 38:546-548. 10.1055/s-2006-949529, 16941283.
18. Ojima A, Ishibashi Y, Matsui T, Maeda S, Nishino Y, Takeuchi M, Fukami K, Yamagishi S. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression. Am J Pathol 2013, 182:132-141. 10.1016/j.ajpath.2012.09.016, 23159951.
19. Si Y, Yonekura H, Yamamoto Y, Katsuno K, Sato F, Mita I, Ooka H, Satozawa N, Kawakami T, Nomura M, Yamamoto H. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem 1997, 272:8723-8730. 10.1074/jbc.272.13.8723, 9079706.
20. Du J, Brink M, Peng T, Mottironi B, Delafontaine P. Thrombin regulates insulin-like growth factor-1 receptor transcription in vascular smooth muscle: characterization of the signaling pathway. Circ Res 2001, 88:1044-1052. 10.1161/hh1001.090840, 11375274.
21. Wei HJ, Li YH, Shi GY, Liu SL, Chang PC, Kuo CH, Wu HL. Thrombomodulin domains attenuate atherosclerosis by inhibiting thrombin-induced endothelial cell activation. Cardiovasc Res 2011, 92:317-327. 10.1093/cvr/cvr220, 21840881.
22. Delekta PC, Apel IJ, Gu S, Siu K, Hattori Y, McAllister-Lucas LM, Lucas PC. Thrombin-dependent NF-{kappa}B activation and monocyte/endothelial adhesion are mediated by the CARMA3 · Bcl10 · MALT1 signalosome. J Biol Chem 2010, 285:41432-41442. 10.1074/jbc.M110.158949, 3009869, 21041303.
23. Lin Z, Hamik A, Jain R, Kumar A, Jain MK. Kruppel-like factor 2 inhibits protease activated receptor-1 expression and thrombin-mediated endothelial activation. Arterioscler Thromb Vasc Biol 2006, 26:1185-1189. 10.1161/01.ATV.0000215638.53414.99, 16514085.
24. Yamagishi S, Nakamura K, Ueda S, Kato S, Imaizumi T. Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF. Cell Tissue Res 2005, 320:437-445. 10.1007/s00441-005-1094-8, 15846509.
25. Yamagishi S, Inagaki Y, Kikuchi S. Nifedipine inhibits tumor necrosis factor-alpha-induced monocyte chemoattractant protein-1 overexpression by blocking NADPH oxidase-mediated reactive oxygen species generation. Drugs Exp Clin Res 2003, 29:147-152.
26. Inagaki Y, Yamagishi S, Okamoto T, Takeuchi M, Amano S. Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia 2003, 46:284-287.
27. Yamagishi S, Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, Okuda S, Imaizumi T. Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species. Ophthalmic Res 2008, 40:10-15. 10.1159/000111152, 18025836.
28. Ishibashi Y, Matsui T, Maeda S, Higashimoto Y, Yamagishi S. Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol 2013, 12:125. 10.1186/1475-2840-12-125, 3765742, 23984879.
29. Yamagishi S, Matsui T, Nakamura K, Takeuchi M, Inoue H. Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammaactivation. Protein Pept Lett 2008, 15:850-853. 10.2174/092986608785203746, 18855759.
30. Kawanami D, Matoba K, Kanazawa Y, Ishizawa S, Yokota T, Utsunomiya K. Thrombin induces MCP-1 expression through Rho-kinase and subsequent p38MAPK/NF-κB signaling pathway activation in vascular endothelial cells. Biochem Biophys Res Commun 2011, 411:798-803. 10.1016/j.bbrc.2011.07.031, 21787749.
31. Xue J, Thippegowda PB, Hu G, Bachmaier K, Christman JW, Malik AB, Tiruppathi C. NF-kappaB regulates thrombin-induced ICAM-1 gene expression in cooperation with NFAT by binding to the intronic NF-kappaB site in the ICAM-1 gene. Physiol Genomics 2009, 38:42-53. 10.1152/physiolgenomics.00012.2009, 2696150, 19351910.
32. Miho N, Ishida T, Kuwaba N, Ishida M, Shimote-Abe K, Tabuchi K, Oshima T, Yoshizumi M, Chayama K. Role of the JNK pathway in thrombin-induced ICAM-1 expression in endothelial cells. Cardiovasc Res 2005, 68:289-298. 10.1016/j.cardiores.2005.05.029, 15979056.
33. Minhajuddin M, Fazal F, Bijli KM, Amin MR, Rahman A. Inhibition of mammalian target of rapamycin potentiates thrombin-induced intercellular adhesion molecule-1 expression by accelerating and stabilizing NF-kappa B activation in endothelial cells. J Immunol 2005, 174:5823-5829.
34. Fukushima Y, Daida H, Morimoto T, Kasai T, Miyauchi K, Yamagishi S, Takeuchi M, Hiro T, Kimura T, Nakagawa Y, Yamagishi M, Ozaki Y, Matsuzaki M, JAPAN-ACS Investigators Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: the JAPAN-ACS sub-study. Cardiovasc Diabetol 2013, 12:5. 10.1186/1475-2840-12-5, 3571912, 23289728, JAPAN-ACS Investigators.
35. Kato T, Yamashita T, Sekiguchi A, Tsuneda T, Sagara K, Takamura M, Kaneko S, Aizawa T, Fu LT. AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat. J Cardiovasc Electrophysiol 2008, 19:415-420. 10.1111/j.1540-8167.2007.01037.x, 18298515.
36. Raposeiras-Roubín S, Rodiño-Janeiro BK, Grigorian-Shamagian L, Seoane-Blanco A, Moure-González M, Varela-Román A, Álvarez E, González-Juanatey JR. Evidence for a role of advanced glycation end products in atrial fibrillation. Int J Cardiol 2012, 157:397-402. 10.1016/j.ijcard.2011.05.072, 21652096.
37. Kubitza D, Becka M, Roth A, Mueck W. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct Factor Xa inhibitor. J Clin Pharmacol 2013, 53:249-255. 10.1002/jcph.5, 23381840.
38. Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med 2000, 6:114-125. 1949938, 10859028.